Drug Profile
HAL MRE1
Alternative Names: HAL-MRE1; HAL-MRE1 subcutaneous immunotherapy - HAL AllergyLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator HAL Allergy
- Class Allergens; Antiallergics; Plant allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Allergic rhinitis; Allergic rhinoconjunctivitis
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Allergic rhinoconjunctivitis in Canada (SC, Suspension)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Allergic-rhinitis in Canada (SC, Suspension)
- 17 May 2019 HAL Allergy completes a phase I trial in Allergic rhinoconjunctivitis and Allergic rhinitis in Canada (SC) (NCT03758456)